Peer Exchange: Spring 2016 Oncology Stakeholders Summit

A Q&A With Peter Bach

May 10, 2016

Evidence-Based Oncology

Peter Bach, MD, MAPP, director, Center for Health and Policy Research, Memorial Sloan Kettering Cancer Center, speaks about DrugAbacus, the importance of using value frameworks, and using the European market as a model to recalibrate the healthcare system in the United States.

Value in Cancer Care: An Economist's Perspective

May 10, 2016

Evidence-Based Oncology

Measuring the quality of oncology care and associating it with reimbursement, and high drug prices remain important concerns of value-based outpatient cancer care. A healthcare economist reviews the current status and suggests a potential path forward.

Q&A With ICER's Steven D. Pearson

May 11, 2016

Evidence-Based Oncology

In this interview, Steven D. Pearson, MD, MSc, FRCP, founder and president of the Institute for Clinical and Economic Review, talks about the various value tools that have been developed, the need for understanding the budgetary impact of healthcare costs, and why stakeholders are interested in innovative models such as indication-based pricing.

In Conversation With ASCO's Richard Schilsky

May 11, 2016

Evidence-Based Oncology

The American Society of Clinical Oncology (ASCO)’s Value Framework evaluates the clinical benefit, toxicity, and cost of new interventions compared with the standard of care. ASCO’s CMO, Richard Schilsky, MD, FACP, FASCO, explains their plans to make the framework useful for clinical decisions at the point of care.

Considerations for Designing "Value Calculators" for Oncology Therapies

May 12, 2016

Evidence-Based Oncology

A review of the various value calculators that have emerged to measure the value of cancer therapies—these calculators reflect the interests of their developers and vary substantially in their intention, format, and usability.